Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults

AIDS

Volumn 22, Issue 17, 2008, Pages 2313-2321

  Carr, Andrew ^a   Ritzhaupt, Armin ^b   Zhang, Wei ^c   Zajdenverg, Roberto ^d   Workman, Cassy ^e   Gatell, Jose M ^f   Cahn, Pedro ^g   Chaves, Ricardo ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e AIDS Research Initiative   (Australia)

^f HOSPITAL CLÍNIC   (Spain)

^g FUNDACIÓN HUÉSPED   (Argentina)

Author keywords

Adiponectin; HIV; Insulin resistance; Lipoatrophy; Protease inhibitors; Visceral adiposity

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LAMIVUDINE; LEPTIN; LOPINAVIR; RITONAVIR; TENOFOVIR; TIPRANAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHNICITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SUBCUTANEOUS FAT; TREATMENT DURATION; VIRUS LOAD; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADULT; BODY COMPOSITION; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; MALE; PYRIDINES; PYRIMIDINONES; PYRONES; RITONAVIR;

EID: 56549125568     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328315a7a5     Document Type: Article

References (36)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
2. Grinspoon SK, Carr A. Cardiovascular risk and body fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
3. Mallon FWC, Miller J, Cooper DA, Carr A. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003; 17:971-979.
4. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50:1378-1388.
5. Kim RJ, Wilson CG, Wabitsch M, Lazar MA, Steppan CM. HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity 2006; 14:994-1002.
6. Jones SP, Janneh O, Back DJ, Pirmohamed M. Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther 2005; 10:207-213.
7. Murphy R, Zhang J, Hafner R, et al. Peripheral and visceral fat changes following a treatment switch to a nonthymidine analogue or nucleoside-sparing regimen in patients with peripheral lipoatrophy: 48-week final results of ACTG5110, a prospective, randomized, multicenter clinical trial [abstract]. Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections. Boston, USA; 2006; p. 755.
8. Dubé MP, Parker RA, Tebas P, Grinspoon SK, Zackin RA, Robbins GK, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19:1807-1818.
9. Jemsek JG, Arathoon E, Arlotti M, Perez C, Sosa N, Pokrovskiy V, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 2006; 42:273-280.
10. Haubrich R, Riddler S, DiRienzo G, et al. Metabolic outcomes of ACTG5142; A prospective, randomised, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection [abstract]. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, California; 2007. p. 38.
11. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomised, multicentre, open-label study. AIDS 2001; 15:1811-1822.
12. Lee GA, Lo JC, Aweeka F, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C. Single-dose lopinavir-ritonavir acutely inhibits insulin-mediated glucose disposal in healthy volunteers. Clin Infect Dis 2006; 43:658-660.
13. Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20:1813-1821.
14. Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R. Adipocyte-derived hormone levels in HIV lipodystrophy. Antiviral Ther 2003; 8:9-15.
15. Petit JM, Duong M, Masson D, Buisson M, Duvillard L, Bour JB, et al. Serum adiponectin and metabolic parameters in HIV-I-infected patients after substitution of nevirapine for protease inhibitors. Eur J Clin Invest 2004; 34:569-575.
16. Lindegaard B, Keller P, Bruunsgaard H, Gerstoft J, Pedersen BK. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin Exp Immunol 2004; 135:273-279.
17. Samaras K, Wand H, Law M, Emery S, Cooper DA, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein and hypoadiponectinemia. Diabetes Care 2007; 30:113-119.
18. Lee GA, Mafong DD, Noor MA, et al. HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr 2004; 36:645-647.
19. Calmy A, Carey D, Mallon PWG, et al. Predictors of lipoatrophy and visceral fat accumulation in men initiating antiretroviral therapy. Antiviral Ther 2005.
20. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
21. Pozniak AL, Gallant JE, Dejesus E, Arribas JR, Gazzard B, Campo RE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes: a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43:535-540.
22. Carr A, Law M, HIV Lipodystrophy Case Definition Study Group. An objective lipodystrophy severity grading scale using the lipodystrophy case definition score. J Acquir Immun Defic Syndr 2003; 33:571-576.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetohgia 1985; 28:412-419.
24. Cooper DA, Zajdenverg R, Ruxrungtham K, Chavez RL. Efficacy and safety of two doses of tipranavir/r versus lopinavir/r-based therapy in antiretroviral naïve patients: results of BH 182.33 trial [abstract]. In: Abstracts of the 8th International Congress on Drug Therapy in HIV Infection. November 12-16, 2006, Glasgow, Scotland; p. PL13.4.
25. Noether GE. Sample size determination for some common nonparametric tests. J Am Stat Association 1987; 82:645-647.
26. Wohl D, Lancaster T, DeJesus E, et al. Determination of body composition changes by total body DEXA after 48 weeks of treatment with once-daily fosamprenavir (FPV) boosted with two different doses of ritonavir(r) plus abacavir (ABC)/lamivudine(3TC):COL100758 [abstract TU PEB080]. In: Abstracts of the 4th IAS Conference on AIDS Pathogenesis. Treatment and Prevention, Sydney, Australia.
27. van Vonderen MGA, Blümer RME, Hassink E, et al. ZDV/3TC persistently contributes to peripheral insulin resistance by a body composition-independent mechanism demonstrated by repeated clamp studies during 2 years of first line ART with ZDV/3TC/LPV/r. Antiviral Ther 2007; 12 Suppl 2:L13.
28. Cameron DW, da Silva B, Arribas J, et al. Significant sparing of peripheral lipoatrophy by HIV treatment with LPV/r + ZDV/3TC induction followed by LPV/R monotherapy compared with EFV + ZDV/3TC [Abstract 44LB]. Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, California; 2007.
29. Malan N, JKrantz E, David N, Mathew M, Rightmire A, Witz V, et al. Efficacy and safety of atazanavir-based therapy in anti-retroviral- naïve HIV-1-infected subjects, both with and without ritonavir: 96-week results from A1424-089 [abstract WEPEB024]. In: Abstracts of the 4th IAS Conference on HIV Pathogenesis, treatment and Prevention. Sydney, Australia; 2007.
30. Nguyen AT, Gagnon A, Angel JB, Sorisky A. Ritonavir increases the level of active ADD-1/SREBP-1 protein during adipogenesis. AIDS 2000; 14:2467-2473.
31. Fleischman A, Johnsen S, Systrom DM, Hrovat M, Farrar CT, Frontera W, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007; 292:E1666-E1673; Epub 2007 Feb 6.
32. Modan-Moses D, Stein D, Pariente C, Yaroslavsky A, Ram A, Faigin M, et al. Modulation of adiponectin and leptin during refeeding of female anorexia nervosa patients. J Clin Endocrinol Metab 2007; 92:1843-1847; Epub 2007 Feb 27.
33. Das S, Shahmanesh M, Stolinski M, Shojaee-Moradie F, Jefferson W, Jackson NC, et al. In treatment-naive and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100. Diabetohgia 2006; 49:538-542.
34. Mynarcik DC, Combs T, McNurlan MA, Scherer PE, Komaroff E, Gelato MC. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 2002; 31:514-520.
35. Xu A, Yin S, Wong L, Chan KW, Lam KS. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 2004; 145:487-494.
36. DAD Study Group. Class of antiretroviral drug and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735.